October 7th 2024
Novel treatment for cocaine use disorder? Researchers performed a randomized, double-blind, placebo-controlled trial of lorcaserin.
September 19th 2024
Meeting the needs of the dying and their families requires a deep and clear understanding of competent and compassionate care.
September 18th 2024
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
PER® Psychiatry Summit
November 7, 2024
View More
2023 Annual Psychiatric Times™ World CME Conference
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Poll: Do You Feel Prepared to Prescribe the Newly Approved First-In-Class Muscarinic Agonist?
September 27th 2024The first-in-class muscarinic agonist Cobenfy, formerly known as KarXT, was just approved by the FDA to treat schizophrenia in adults. Are you ready to discuss it with patients and caregivers?